BACKGROUND: Medical comorbidity is a confounding factor in prostate cancer (PCa) treatment selection and mortality. Large-scale comparative evaluation of PCa mortality (PCM) and overall mortality (OM) restricted to men without comorbidity at the time of treatment has not been performed. OBJECTIVE: To evaluate PCM and OM in men with no recorded comorbidity treated with radical prostatectomy (RP), external-beam radiation therapy (EBRT), or brachytherapy (BT). DESIGN, SETTING, AND PARTICIPANTS: Data from 10 361 men with localized PCa treated from 1995 to 2007 at two academic centers in the United States were prospectively obtained at diagnosis and retrospectively reviewed. We identified 6692 men with no recorded comorbidity on a validated comorbidity index. Median follow-up after treatment was 7.2 yr. INTERVENTION: Treatment with RP in 4459 men, EBRT in 1261 men, or BT in 972 men. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariate and multivariate Cox proportional hazards regression analysis, including propensity score adjustment, compared PCM and OM for EBRT and BT relative to RP as reference treatment category. PCM was also evaluated by competing risks analysis. RESULTS AND LIMITATIONS: Using Cox analysis, EBRT was associated with an increase in PCM compared with RP (hazard ratio [HR]: 1.66; 95% confidence interval [CI], 1.05-2.63), while there was no statistically significant increase with BT (HR: 1.83; 95% CI, 0.88-3.82). Using competing risks analysis, the benefit of RP remained but was no longer statistically significant for EBRT (HR: 1.55; 95% CI, 0.92-2.60) or BT (HR: 1.66; 95% CI, 0.79-3.46). In comparison with RP, both EBRT (HR: 1.71; 95% CI, 1.40-2.08) and BT (HR: 1.78; 95% CI, 1.37-2.31) were associated with increased OM. CONCLUSIONS: In a large multicenter series of men without recorded comorbidity, both forms of radiation therapy were associated with an increase in OM compared with surgery, but there were no differences in PCM when evaluated by competing risks analysis. These findings may result from an imbalance of confounders or differences in mortality related to primary or salvage therapy.
BACKGROUND: Medical comorbidity is a confounding factor in prostate cancer (PCa) treatment selection and mortality. Large-scale comparative evaluation of PCa mortality (PCM) and overall mortality (OM) restricted to men without comorbidity at the time of treatment has not been performed. OBJECTIVE: To evaluate PCM and OM in men with no recorded comorbidity treated with radical prostatectomy (RP), external-beam radiation therapy (EBRT), or brachytherapy (BT). DESIGN, SETTING, AND PARTICIPANTS: Data from 10 361 men with localized PCa treated from 1995 to 2007 at two academic centers in the United States were prospectively obtained at diagnosis and retrospectively reviewed. We identified 6692 men with no recorded comorbidity on a validated comorbidity index. Median follow-up after treatment was 7.2 yr. INTERVENTION: Treatment with RP in 4459 men, EBRT in 1261 men, or BT in 972 men. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariate and multivariate Cox proportional hazards regression analysis, including propensity score adjustment, compared PCM and OM for EBRT and BT relative to RP as reference treatment category. PCM was also evaluated by competing risks analysis. RESULTS AND LIMITATIONS: Using Cox analysis, EBRT was associated with an increase in PCM compared with RP (hazard ratio [HR]: 1.66; 95% confidence interval [CI], 1.05-2.63), while there was no statistically significant increase with BT (HR: 1.83; 95% CI, 0.88-3.82). Using competing risks analysis, the benefit of RP remained but was no longer statistically significant for EBRT (HR: 1.55; 95% CI, 0.92-2.60) or BT (HR: 1.66; 95% CI, 0.79-3.46). In comparison with RP, both EBRT (HR: 1.71; 95% CI, 1.40-2.08) and BT (HR: 1.78; 95% CI, 1.37-2.31) were associated with increased OM. CONCLUSIONS: In a large multicenter series of men without recorded comorbidity, both forms of radiation therapy were associated with an increase in OM compared with surgery, but there were no differences in PCM when evaluated by competing risks analysis. These findings may result from an imbalance of confounders or differences in mortality related to primary or salvage therapy.
Authors: S Houterman; M L G Janssen-Heijnen; A J M Hendrikx; H A van den Berg; J W W Coebergh Journal: Crit Rev Oncol Hematol Date: 2005-10-05 Impact factor: 6.312
Authors: Patti A Groome; Susan L Rohland; D Robert Siemens; Michael D Brundage; Jeremy Heaton; William J Mackillop Journal: Cancer Date: 2011-02-24 Impact factor: 6.860
Authors: A Kutikov; M R Cooperberg; A T Paciorek; R G Uzzo; P R Carroll; S A Boorjian Journal: Prostate Cancer Prostatic Dis Date: 2012-06-19 Impact factor: 5.554
Authors: Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Pär Stattin; Erik Holmberg; Jan-Erik Johansson; Lars Holmberg; Jan Adolfsson; Jonas Hugosson Journal: J Natl Cancer Inst Date: 2010-06-18 Impact factor: 13.506
Authors: Pedro Recabal; Melissa Assel; John E Musser; Ronald J Caras; Daniel D Sjoberg; Jonathan A Coleman; John P Mulhall; Raul O Parra; Peter T Scardino; Karim Touijer; James A Eastham; Vincent P Laudone Journal: J Urol Date: 2016-02-22 Impact factor: 7.450
Authors: Henk van der Poel; Laurence Klotz; Gerald Andriole; Abdel-Rahmène Azzouzi; Anders Bjartell; Olivier Cussenot; Freddy Hamdy; Markus Graefen; Paolo Palma; Arturo Rodriguez Rivera; Christian G Stief Journal: World J Urol Date: 2015-06-03 Impact factor: 4.226
Authors: Pirus Ghadjar; Alberto Briganti; Peter J L De Visschere; Jurgen J Fütterer; Gianluca Giannarini; Hendrik Isbarn; Piet Ost; Prasanna Sooriakumaran; Christian I Surcel; Roderick C N van den Bergh; Inge M van Oort; Ofer Yossepowitch; Guillaume Ploussard Journal: World J Urol Date: 2014-07-05 Impact factor: 4.226
Authors: Zachary S Zumsteg; Daniel E Spratt; Paul B Romesser; Xin Pei; Zhigang Zhang; Marisa Kollmeier; Sean McBride; Yoshiya Yamada; Michael J Zelefsky Journal: J Urol Date: 2015-07-10 Impact factor: 7.450
Authors: Kenan Celtik; Christopher J D Wallis; Mary Lo; Kelvin Lim; Joseph Lipscomb; Steven Fleming; Xiao-Cheng Wu; Roger T Anderson; Trevor D Thompson; Andrew Farach; Ann S Hamilton; Brian J Miles; Raj Satkunasivam Journal: Can Urol Assoc J Date: 2022-07 Impact factor: 2.052